Madrigal Pharmaceuticals, Inc. (MDGL) News
Filter MDGL News Items
MDGL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MDGL News Highlights
- For MDGL, its 30 day story count is now at 6.
- Over the past 15 days, the trend for MDGL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about MDGL are BIO, DEC and DRUG.
Latest MDGL News From Around the Web
Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to thirty-two new employees with a grant date of December 19, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company's 2023 Inducement Plan. The equity awards were approved in |
Senior VP Robert Waltermire Sells 4,000 Shares of Madrigal Pharmaceuticals Inc (MDGL)In a recent transaction on December 15, 2023, Robert Waltermire, Senior Vice President and Chief of Pharmaceutical Development at Madrigal Pharmaceuticals Inc, sold 4,000 shares of the company's stock. |
11 Stocks Insiders and Billionaires Are Crazy AboutIn this article, we will take a detailed look at the 11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled One Up on Wall Street, Peter Lynch talks about how average investors miss out on opportunities by […] |
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To ProfitMadrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) is possibly approaching a major achievement in its business, so we would... |
Insider Sell Alert: Senior VP Robert Waltermire Sells 3,800 Shares of Madrigal Pharmaceuticals IncMadrigal Pharmaceuticals Inc (NASDAQ:MDGL) has recently witnessed a significant insider sell that has caught the attention of investors and market analysts. |
These 2 Stocks Could Be About to Soar: Are They Buys?Shares of relatively small biotech companies often soar when they get positive news from regulators, and that's exactly what Madrigal Pharmaceuticals (NASDAQ: MDGL) and Bluebird Bio (NASDAQ: BLUE) are awaiting. Madrigal Pharmaceuticals is a clinical-stage biotech that may have made a significant breakthrough. Madrigal submitted an application for resmetirom, its potential NASH therapy, to the Food and Drug Administration (FDA) for review in July. |
11 Best Upside Stocks To Buy Right NowIn this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has always gone hand in hand […] |
Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist InvestorsOrbiMed Advisors is part of a partnership interested in acquiring all of Kinnate Biopharma. Baker Brothers increased an investment in Madrigal Pharmaceuticals. |
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information OfficerCONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer. Mr. Filippo has more than 25 years of digital experience in the biopharmaceutical industry and was previously Senior Vice President Digital at Moderna, where he was responsible for technology leadership and |
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS RatingMadrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. |